{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:38:56Z","timestamp":1773326336458,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/mjt.0b013e31818f9eae","type":"journal-article","created":{"date-parts":[[2010,1,12]],"date-time":"2010-01-12T08:33:32Z","timestamp":1263285212000},"page":"17-22","source":"Crossref","is-referenced-by-count":33,"title":["Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases"],"prefix":"10.1097","volume":"17","author":[{"given":"Parvaneh","family":"Baghaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payam","family":"Tabarsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Chitsaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Marjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Shemirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid Valiollah","family":"Pooramiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Kazempour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Farnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanak","family":"Fahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davood","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Masjedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210202","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1183\/09031936.95.08081247","article-title":"The dark side of antituberculosis therapy: adverse events involving liver function.","volume":"4","author":"Shaberg","year":"1995","journal-title":"Eur Respir J"},{"key":"R2-4-20210202","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1164\/ajrccm.149.5.8173779","article-title":"Treatment of tuberculosis and tuberculosis infection in adults and children.","volume":"149","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-4-20210202","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur Respir J"},{"key":"R4-4-20210202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/thx.51.2.111","article-title":"Hepatotoxicity of antituberculosis drugs.","volume":"51","author":"Ormerod","year":"1996","journal-title":"Thorax"},{"key":"R5-4-20210202","first-page":"991","article-title":"Isoniazid-related hepatitis.","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"R6-4-20210202","first-page":"151","article-title":"Isoniazid hepatitis among pregnant and postpartum Hispanic patients.","volume":"104","author":"Franks","year":"1989","journal-title":"Public Health Rep"},{"key":"R7-4-20210202","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/hep.1840210407","article-title":"Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculosis treatment including isoniazid.","volume":"21","author":"Durand","year":"1995","journal-title":"Hepatology"},{"key":"R8-4-20210202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/thx.45.5.403","article-title":"Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Committee of the British Thoracic Society.","volume":"45","author":"Ormerod","year":"1990","journal-title":"Thorax"},{"key":"R10-4-20210202","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-2002-30105","article-title":"Epidemiology and individual susceptibility to adverse drug reactions affecting the liver.","volume":"22","author":"Larrey","year":"2002","journal-title":"Semin Liver Dis"},{"key":"R11-4-20210202","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"R12-4-20210202","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"American Thoracic Society, An official ATS Statement: hepatotoxicity of antituberculosis therapy.","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R14-4-20210202","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"American Thoracic Society Documents. An Official ATS Statement: hepatotoxicity of antituberculosis therapy.","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-4-20210202","first-page":"44","article-title":"Incidence of hepatotoxicity due to antitubercular medicine and assessment of risk factors, Zahedan, Iran.","volume":"6","author":"Sharifi-Mood","year":"2006","journal-title":"J Med Sci"},{"key":"R16-4-20210202","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.","volume":"166","author":"Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R17-4-20210202","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1164\/rccm.2207001","article-title":"Treatment, tuberculosis, and human leukocyte antigen [editorial].","volume":"166","author":"Bothamley","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-4-20210202","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"R19-4-20210202","first-page":"78","article-title":"Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment.","volume":"11","author":"Pukenyte","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"R20-4-20210202","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-4-20210202","first-page":"921","article-title":"Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara.","volume":"129","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"R22-4-20210202","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1345\/aph.1D525","article-title":"Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors.","volume":"38","author":"Shakya","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R23-4-20210202","first-page":"1499","article-title":"The influence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity.","volume":"8","author":"Fernandez-Villar","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"R24-4-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection.","volume":"31","author":"Wong","year":"2000","journal-title":"Hepatology"},{"key":"R25-4-20210202","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Anti-tuberculosis drug induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"R26-4-20210202","first-page":"403","article-title":"The changing epidemiology of viral hepatitis B in Iran.","volume":"16","author":"Alavian","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"key":"R27-4-20210202","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.26719\/2000.6.5-6.1114","article-title":"Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran.","volume":"6","author":"Ghavanini","year":"2000","journal-title":"East Mediterr Health J"},{"key":"R28-4-20210202","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0962-8479(96)90098-2","article-title":"Liver injury during antituberculosis treatment: an 11-year study.","volume":"77","author":"Dossing","year":"1996","journal-title":"Tuber Lung Dis"},{"key":"R29-4-20210202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0962-8479(96)90073-8","article-title":"Frequency and type of reactions to antituberculosis drugs: observations in routine treatment.","volume":"77","author":"Ormerod","year":"1996","journal-title":"Tuber Lung Dis"},{"key":"R30-4-20210202","first-page":"699","article-title":"Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.","volume":"6","author":"Teleman","year":"2002","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201001000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T03:57:39Z","timestamp":1634702259000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201001000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31818f9eae","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}